Drug Profile
Research programme: recombinant Midkine protein - Cellmid
Alternative Names: CMK 103Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Cellmid
- Class Recombinant proteins
- Mechanism of Action Apoptosis inhibitors; MDK protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Myocardial infarction in Australia (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Myocardial-infarction in Australia (Parenteral)
- 13 Jul 2016 Preclinical development is ongoing in Australia with Cellmid and its subsidiary Kinera